Friday, May 17, 2024
In-Med Prognostics offers neuro analysis that helps in the early detection of neurological disorders such as Alzheimer’s, Dementia and Parkinson’s at affordable prices. The funds will be utilized for product portfolio development and tap into the worldwide markets.
In-Med Prognostics, a Neurological healthcare startup, raises $2.13 million in funding led by Exxora
Healthtech startup In-Med Prognostics has raised $2.13 million, led by investment firm Exxora with the participation of other angel investors. The company will use the fund to expand its product portfolio and tap global markets.
In-Med offers AI-powered image processing software for radiologists and neurologists to enhance workflow. This analysis helps assess and detect neurological disorders such as dementia, Alzheimer’s and Parkinson’s at affordable prices.
The Pune-based startup was founded in 2018 by Latha Poonamallee and Rajesh Purshottam. Its holding company InMed Inc, is based out of the US. In-Med received a Rs 50 lakh grant from Biotechnology Industry Research Assistance Council (BIRAC) in 2019.
Sriram Natarajan, director, Exxora stated, “Medtech is seeing some opportunities and we continue to invest in startups like In-Med Prognostics that are providing innovative solutions in the area of preventive brain health using AI & deep learning.”
The company plans to expand to Africa and has been associated with diagnostic care service organizations in India like Gujarat Scans, Aarthi Scans, Scansworld, Nanavati and Cauvery Hospitals.
(Edited by Rajeev Pillai)
.jpg)
